Prosthetic Joint Infections and Cost Analysis?

Area of Science:

• Orthopedic Surgery
• Infectious Diseases
• Health Economics

Background:

• Prosthetic joint infection (PJI) is a severe complication of arthroplasty, causing patient morbidity and high healthcare expenses.
• The increasing number of arthroplasty procedures worldwide escalates the financial burden of infection revisions.
• Effective infection prevention and management are crucial for reducing morbidity and healthcare costs.

Purpose of the Study:

• To highlight the need for high-quality cost analysis data on different prosthetic joint infection treatment strategies.
• To inform future management strategies aimed at minimizing healthcare expenditure and patient mortality/morbidity.
• To address the growing financial impact of prosthetic joint infection revisions on global healthcare budgets.

Main Methods:

• Review of current management shifts towards cost-effective strategies like 1-stage revision and debridement, antibiotics, and implant retention (DAIR).
• Analysis of the financial implications of these strategies in the context of rising arthroplasty revision rates.
• Emphasis on the need for robust cost-effectiveness data collection following the 2011 consensus on PJI definition.

Main Results:

• Projected healthcare expenditure for prosthetic joint infection revision in the US alone is US$1.62 billion.
• Current management trends favor less expensive approaches, but comprehensive cost data is lacking.
• There is a critical need for data to guide optimal, cost-effective treatment decisions.

Conclusions:

• High-quality cost analysis data is urgently required to evaluate the economic impact of various prosthetic joint infection treatment strategies.
• Informed decision-making based on cost-effectiveness can help mitigate the significant financial burden of PJI on healthcare systems.
• Optimizing treatment strategies for prosthetic joint infection is essential for both patient outcomes and economic sustainability.